Remdesivir Distribution Improvements Among Goals Of US HHS Data Reporting Overhaul
Executive Summary
Gilead’s COVID treatment will be the first product tracked in a system that could eventually help allocate vaccines and other therapeutics.
You may also be interested in...
HHS Shifts Remdesivir Distribution To Gilead As Supply Crunch Eases
AmerisourceBergen will continue to serve as the sole US distributor of Veklury (remdesivir) through the end of this year and will continue to sell the the COVID-19 treatment directly to hospitals.
Medicare’s New Codes For Remdesivir, Convalescent Plasma To Be Test Of Real-World, Though Not Real-Time, Data
CMS’s new procedure reimbursement codes will help generate ‘critical information’ on the effectiveness of the COVID products, but will suffer from a ‘claims lag.’
Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.